Rani Therapeutics Holdings, Inc. (RANI) Institutional Ownership

Ownership Summary

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) showed up in the 13F filings of 63 institutional investors as of December 2025.

• They owned 96.5% of outstanding stock in December 2025, up from 8.6% the prior quarter.
• They increased total shares held in Rani Therapeutics Holdings by 1365.44% from last quarter, and the number of investors in RANI increased 43.18% annually.
• Activity in RANI broke down as 51 buyers, 0 sellers, and 12 unchanged among 63 total holders.
• The aggregate institutional position in Rani Therapeutics Holdings amounted to 44.8Mn shares as of December 2025, up by 41.74Mn shares quarter on quarter, and up 40.97Mn shares year over year.
• As of December 31, 2025, the biggest holder of Rani Therapeutics Holdings is RA CAPITAL MANAGEMENT, L.P. at 8.5Mn shares, representing 18.3% of shares outstanding.
• Leading buyers of Rani Therapeutics Holdings shares for the quarter ending December 2025 were RA CAPITAL MANAGEMENT, L.P. (8.5Mn), Samsara BioCapital, LLC (8.5Mn), AWM Investment Company, Inc. (6.5Mn), SymBiosis Capital Partners, LLC (6.3Mn), VANGUARD GROUP INC (4.22Mn).
• Rani Therapeutics Holdings's 10 largest shareholders as of December 2025 include RA CAPITAL MANAGEMENT, L.P. (8.5Mn), Samsara BioCapital, LLC (8.5Mn), AWM Investment Company, Inc. (6.5Mn), SymBiosis Capital Partners, LLC (6.3Mn), VANGUARD GROUP INC (5.11Mn), Longaeva Partners L.P. (2.11Mn), Siren, L.L.C. (2.0Mn), GEODE CAPITAL MANAGEMENT, LLC (860.94K), BlackRock, Inc. (527.71K), Nan Fung Group Holdings Ltd (493.58K) per Business Quant data.